Medmix (SWX:MEDX) Stock Faces Tiny Profit After One Off Loss Tests Bullish Narratives

medmix (SWX:MEDX) has reported H1 2026 results with trailing 12 month revenue of CHF437 million and net income of CHF0.1 million, translating to EPS of CHF0.002. The latest reported half year for 2025 showed revenue of CHF222.6 million and a net loss of CHF0.4 million, or EPS of CHF0.0096. Over the last few reported periods, revenue has moved from CHF242.7 million in H2 2024 to CHF225.4 million in H1 2025 and CHF222.6 million in H2 2025. Over the same timeframe, EPS shifted from a loss of CHF0.303 in H2 2024 to EPS of CHF0.17 in H1 2025 before slipping back into a smaller loss in H2 2025. This places tighter attention on how margins and profitability are stabilising around the latest numbers.

See our full analysis for medmix.

With the headline figures in place, the next step is to see how medmix’s recent results line up against the prevailing narratives around its earnings trajectory, risks, and potential rewards.

See what the community is saying about medmix

Profit swing and one off item in the rear view

• On a trailing 12 month basis, medmix moved from a loss of CHF5.8 million in H1 2025 to a small profit of CHF0.1 million in H1 2026, while still carrying a CHF5.2 million one off loss in that period.
• Bulls point out that this return to profit, together with a forecast 68.1% annual earnings growth rate, sits alongside product launches in areas like PiccoJect, D Flex and the CliX applicator. However, the presence of a CHF5.2 million one off loss means reported margins look weaker than what the underlying operations alone would suggest.
  • Supporters of the bullish view focus on Dental and Surgery, where higher value procedures and systems such as the Vented G System and CliX are aimed at higher margin work, while trailing data still shows only CHF0.002 EPS for the last 12 months.
  • This mix of small reported profit today and strong growth expectations highlights how much of the bullish case depends on those healthcare projects moving from development into full commercial supply.

For a closer look at how recent earnings tie into the more optimistic long term story that some investors see for medmix, you can check out the 🐂 medmix Bull Case

Revenue cooling while forecasts stay ambitious

• Reported revenue stepped down from CHF242.7 million in H2 2024 to CHF225.4 million in H1 2025 and CHF222.6 million in H2 2025, while revenue growth is forecast at about 5.2% per year, slightly below the 5.3% Swiss market forecast.
• Bears argue that this pattern of declining recent revenue, together with weaker segments in Beauty and Drug Delivery, makes the forecast growth rates look demanding, especially when some recent Dental demand has been pulled forward due to U.S. tariff concerns.
  • The cautious narrative highlights that organic volume in parts of the group has already come under pressure and that dual sourcing by Drug Delivery customers could limit how much of that forecast 5.2% annual growth actually shows up in reported revenue.
  • At the same time, execution risks around new facilities such as the Atlanta site and around launches like PiccoJect and D Flex could slow how quickly higher value healthcare projects offset softness in areas where activity has been held back.

If you want to see how skeptics frame these slowing revenue trends against medmix’s project pipeline and cost programs, take a look at the 🐻 medmix Bear Case

Low P/S and DCF gap frame valuation debate

• medmix trades on a P/S of 0.8x versus peers at 3.2x and the wider European Medical Equipment industry at 2.8x, while a DCF fair value of CHF15.32 and an analyst price target of CHF15.80 both sit well above the current CHF8.19 share price.
• Supporters of the consensus narrative see this mix of a lower P/S and a DCF fair value above the market price as a potential opportunity, yet they also flag that five year earnings declined at about 66.1% per year and that the recent profit is very small, at CHF0.1 million over the last 12 months.
  • On one side, the gap between the CHF8.19 share price and both the CHF15.32 DCF fair value and CHF15.80 consensus target suggests analysts expect earnings and margins to improve from current levels.
  • On the other side, the history of multi year earnings declines and the effect of one off items in the recent period mean some investors may want to see a longer run of cleaner profits before putting too much weight on those valuation signals.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for medmix on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of cautious and optimistic signals around medmix, it makes sense to review the full picture quickly and decide where you stand. A good place to start is the 5 key rewards and 1 important warning sign.

See What Else Is Out There Beyond medmix

medmix shows weakening recent revenue, tiny trailing profits and dependence on one off items and ambitious forecasts, which leaves some investors questioning the resilience of the story.

If that mix of fragile profitability and uneven revenue trends makes you cautious, it is worth lining up steadier options by scanning the 293 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com